SUDO-550 demonstrated favorable safety, tolerability, and once-daily pharmacokinetic profile with full central nervous system (CNS) penetration Achieved exposure levels associated with >90% inhibition ...
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will be featured in two ...
Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study ...
A myasthenia gravis treatment revolution has taken place in the past four years, spurred by an initial approval for argenx’s ...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...
Iopofosine I 131 is a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy. The FDA previously granted Orphan Drug Designation for ...
Tolerance Bio, a biopharmaceutical company pioneering innovative approaches to extending healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of ...
Merck and Eisai Announce WELIREG® Plus LENVIMA® Met Primary Endpoint of PFS in Certain Previously Treated Patients With ...
Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback